Spotlight Innovation Inc. (OTCQB: STLT) has entered into a Sponsored Research Agreement with Florida State University (FSU) to support research directed by FSU Prof. Hengli Tang aimed at developing safe and effective drugs to treat patients infected with Zika virus (ZIKV).
Prof. Tang is an accomplished virologist whose research has been published in prominent academic journals including Cell and Journal of Virology. In March 2016, Prof. Tang co-authored a study1 published in Cell Stem Cell
that demonstrated for the first time the ability of ZIKV to target
human embryonic cortical neural progenitor cells. After infecting these
crucial brain development cells, the virus replicates and interferes
with cell growth, function and viability. ZIKV infection in pregnant
women can cause neurological birth defects, including microcephaly, a
condition in which a child is born with an abnormally small head as a
result of incomplete brain development.
Geoffrey Laff,
Ph.D., Spotlight Innovation's Senior Vice President of Business
Development, commented, "Prof. Tang is a true pioneer in the scientific
community's efforts to combat Zika virus. We are thrilled that he has
chosen to collaborate with us to develop novel therapies for Zika virus
infection."
About Spotlight Innovation Inc.
Spotlight Innovation Inc.
(OTCQB: STLT) identifies and acquires rights to innovative, proprietary
technologies designed to address unmet medical needs, with an emphasis
on rare, emerging and neglected diseases. To find and evaluate unique
opportunities, we leverage our extensive relationships with leading
scientists, academic institutions and other sources. We provide
value-added development capability to accelerate development progress.
When scientifically significant benchmarks have been achieved, we will
endeavor to partner with proven market leaders via sale, out-license or
strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.
No comments:
Post a Comment